POMALYST- pomalidomide capsule 
Celgene Corporation

----------

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use POMALYST safely and effectively. See full prescribing information for POMALYST.

POMALYST® (pomalidomide) capsules, for oral use
Initial U.S. Approval: 2013

WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM

See full prescribing information for complete boxed warning

EMBRYO-FETAL TOXICITY

  • POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe life-threatening birth defects (4, 5.1, 8.1).
  • For females of reproductive potential: Exclude pregnancy before start of treatment. Prevent pregnancy during treatment by the use of 2 reliable methods of contraception (5.1, 8.6).

POMALYST is available only through a restricted program called POMALYST REMS® (5.2).

VENOUS AND ARTERIAL THROMBOEMBOLISM

  • Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with POMALYST. Antithrombotic prophylaxis is recommended (5.3).

RECENT MAJOR CHANGES

Boxed Warning    04/15
Indications and Usage (1.1)    04/15
Dosage and Administration (2.1, 2.2)    04/15
Warnings and Precautions (5.3, 5.4, 5.5, 5.6, 5.7, 5.8)    04/15
Warnings and Precautions (5.10)    05/14

INDICATIONS AND USAGE

POMALYST is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy (1.1).

DOSAGE AND ADMINISTRATION

4 mg per day taken orally on Days 1-21 of repeated 28-day cycles until disease progression (2.1). Refer to section 14.1 for dexamethasone dosing (14.1).

DOSAGE FORMS AND STRENGTHS

Capsules: 1 mg, 2 mg, 3 mg, and 4 mg (3)

CONTRAINDICATIONS

  • Pregnancy (4)

WARNINGS AND PRECAUTIONS

  • Hematologic Toxicity: Neutropenia was the most frequently reported Grade 3/4 adverse event. Monitor patients for hematologic toxicities, especially neutropenia (5.4).
  • Hepatotoxicity: Hepatic failure including fatalities; monitor liver function tests monthly (5.5).
  • Hypersensitivity Reactions: Angioedema and severe dermatologic reactions have been reported. Discontinue POMALYST for angioedema and severe dermatologic reactions (5.6).
  • Tumor Lysis Syndrome (TLS): Monitor patients at risk of TLS (i.e., those with high tumor burden) and take appropriate precautions (5.10).

ADVERSE REACTIONS

Most common adverse reactions (≥30%) included fatigue and asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upper-respiratory tract infections, back pain and pyrexia (6.1).

  

To report SUSPECTED ADVERSE REACTIONS, contact Celgene Corporation at 1-888-423-5436 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Strong CYP1A2 Inhibitors: Avoid the use of strong CYP1A2 inhibitors unless medically necessary (2.3, 7.1, 12.3).

USE IN SPECIFIC POPULATIONS

  • Nursing Mothers: Discontinue drug or nursing taking into consideration importance of drug to mother (8.3).
  • Avoid POMALYST in patients with serum creatinine >3.0 mg/dL (8.7).

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 4/2015

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM

1 INDICATIONS AND USAGE

1.1 Multiple Myeloma

2 DOSAGE AND ADMINISTRATION

2.1 Multiple Myeloma

2.2 Dose Adjustments for Toxicities

2.3 Dose Adjustment for Strong CYP1A2 Inhibitors in the Presence of Strong CYP3A4 and P-gp Inhibitors

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

Pregnancy

5 WARNINGS AND PRECAUTIONS

5.1 Embryo-Fetal Toxicity

5.2 POMALYST REMS Program

5.3 Venous and Arterial Thromboembolism

5.4 Hematologic Toxicity

5.5 Hepatotoxicity

5.6 Hypersensitivity Reactions

5.7 Dizziness and Confusional State

5.8 Neuropathy

5.9 Risk of Second Primary Malignancies

5.10 Tumor Lysis Syndrome

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Postmarketing Experience

7 DRUG INTERACTIONS

7.1 Drugs That May Increase Pomalidomide Plasma Concentrations

7.2 Drugs That May Decrease Pomalidomide Plasma Concentrations

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

8.6 Females of Reproductive Potential and Males

8.7 Renal Impairment

8.8 Hepatic Impairment

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 Multiple Myeloma

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

16.2 Storage

16.3 Handling and Disposal

17 PATIENT COUNSELING INFORMATION

*
Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM

Embryo-Fetal Toxicity

POMALYST is only available through a restricted distribution program called POMALYST REMS [see Warnings and Precautions (5.2)].

Venous and Arterial Thromboembolism

1 INDICATIONS AND USAGE

1.1 Multiple Myeloma

POMALYST, in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

2 DOSAGE AND ADMINISTRATION

2.1 Multiple Myeloma

Females of reproductive potential must have negative pregnancy testing and use contraception methods before initiating POMALYST [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].

The recommended starting dose of POMALYST is 4 mg once daily orally on Days 1-21 of repeated 28-day cycles until disease progression. POMALYST should be given in combination with dexamethasone [see Clinical Studies (14.1)].

POMALYST may be taken with water. Inform patients not to break, chew, or open the capsules. POMALYST should be taken without food (at least 2 hours before or 2 hours after a meal).

2.2 Dose Adjustments for Toxicities

Table 1: Dose Modification Instructions for POMALYST for Hematologic Toxicities
ANC, absolute neutrophil count
  Toxicity   Dose Modification
  Neutropenia
  • ANC <500 per mcL or febrile neutropenia (fever more than or equal to 38.5°C and ANC <1,000 per mcL)

  • ANC return to more than or equal to 500 per mcL

  • Interrupt POMALYST treatment, follow CBC weekly

  • Resume POMALYST treatment at 3 mg daily
  • For each subsequent drop <500 per mcL

  • Return to more than or equal to 500 per mcL
  • Interrupt POMALYST treatment

  • Resume POMALYST treatment at 1 mg less than the previous dose
  Thrombocytopenia
  • Platelets <25,000 per mcL

  • Platelets return to >50,000 per mcL

  • Interrupt POMALYST treatment, follow CBC weekly

  • Resume POMALYST treatment at 3 mg daily
  • For each subsequent drop <25,000 per mcL

  • Return to more than or equal to 50,000 per mcL
  • Interrupt POMALYST treatment

  • Resume POMALYST treatment at 1 mg less than previous dose

To initiate a new cycle of POMALYST, the neutrophil count must be at least 500 per mcL and the platelet count must be at least 50,000 per mcL. If toxicities occur after dose reductions to 1 mg, then discontinue POMALYST.

Permanently discontinue POMALYST for angioedema, skin exfoliation, bullae, or any other severe dermatologic reaction [see Warnings and Precautions (5.6)].

For other Grade 3 or 4 toxicities, hold treatment and restart treatment at 1 mg less than the previous dose when toxicity has resolved to less than or equal to Grade 2 at the physician’s discretion.

2.3 Dose Adjustment for Strong CYP1A2 Inhibitors in the Presence of Strong CYP3A4 and P-gp Inhibitors

Avoid co-administration of strong inhibitors of CYP1A2. If necessary to co-administer strong inhibitors of CYP1A2 in the presence of strong inhibitors of CYP3A4 and P-gp, reduce POMALYST dose by 50%. No clinical efficacy or safety data exist [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

3 DOSAGE FORMS AND STRENGTHS

POMALYST is available in the following capsule strengths:

1 mg: Dark blue opaque cap and yellow opaque body, imprinted “POML” on the cap in white ink and “1 mg” on the body in black ink
2 mg: Dark blue opaque cap and orange opaque body, imprinted “POML” on the cap and “2 mg” on the body in white ink
3 mg: Dark blue opaque cap and green opaque body, imprinted “POML” on the cap and “3 mg” on the body in white ink
4 mg: Dark blue opaque cap and blue opaque body, imprinted “POML” on the cap and “4 mg” on the body in white ink

4 CONTRAINDICATIONS

Pregnancy

POMALYST can cause fetal harm when administered to a pregnant female [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. POMALYST is contraindicated in females who are pregnant. Pomalidomide is a thalidomide analogue and is teratogenic in both rats and rabbits when administered during the period of organogenesis. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

5 WARNINGS AND PRECAUTIONS

5.1 Embryo-Fetal Toxicity

POMALYST is a thalidomide analogue and is contraindicated for use during pregnancy. Thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal death [see Use in Specific Populations (8.1)]. POMALYST is only available through the POMALYST REMS program [see Warnings and Precautions (5.2)].

Females of Reproductive Potential
Females of reproductive potential must avoid pregnancy while taking POMALYST and for at least 4 weeks after completing therapy.

Females must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy.

Two negative pregnancy tests must be obtained prior to initiating therapy. The first test should be performed within 10-14 days and the second test within 24 hours prior to prescribing POMALYST therapy and then weekly during the first month, then monthly thereafter in women with regular menstrual cycles, or every 2 weeks in women with irregular menstrual cycles [see Use in Specific Populations (8.6)].

Males
Pomalidomide is present in the semen of patients receiving the drug. Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking POMALYST and for up to 28 days after discontinuing POMALYST, even if they have undergone a successful vasectomy. Male patients taking POMALYST must not donate sperm [see Use in Specific Populations (8.6)].

Blood Donation
Patients must not donate blood during treatment with POMALYST and for 1 month following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to POMALYST.

5.2 POMALYST REMS Program

Because of the embryo-fetal risk [see Warnings and Precautions (5.1)], POMALYST is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called “POMALYST REMS.”

Required components of the POMALYST REMS program include the following:

  • Prescribers must be certified with the POMALYST REMS program by enrolling and complying with the REMS requirements.
  • Patients must sign a Patient-Physician Agreement Form and comply with the REMS requirements. In particular, female patients of reproductive potential who are not pregnant must comply with the pregnancy testing and contraception requirements [see Use in Specific Populations (8.6)] and males must comply with contraception requirements [see Use in Specific Populations (8.6)].
  • Pharmacies must be certified with the POMALYST REMS program, must only dispense to patients who are authorized to receive POMALYST, and comply with REMS requirements.

Further information about the POMALYST REMS program is available at www.CelgeneRiskManagement.com or by telephone at 1-888-423-5436.

5.3 Venous and Arterial Thromboembolism

Venous thromboembolic events (deep venous thrombosis and pulmonary embolism) and arterial thromboembolic events (myocardial infarction and stroke) have been observed in patients treated with POMALYST. In Trial 2, where anticoagulant therapies were mandated, thromboembolic events occurred in 8.0% of patients treated with POMALYST and low dose-dexamethasone (Low-dose Dex), and 3.3% of patients treated with high-dose dexamethasone. Venous thromboembolic events (VTE) occurred in 4.7% of patients treated with POMALYST and Low-dose Dex, and 1.3% of patients treated with high-dose dexamethasone. Arterial thromboembolic events include terms for arterial thromboembolic events, ischemic cerebrovascular conditions, and ischemic heart disease. Arterial thromboembolic events occurred in 3.0% of patients treated with POMALYST and Low-dose Dex, and 1.3% of patients treated with high-dose dexamethasone.

Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors.

5.4 Hematologic Toxicity

In trials 1 and 2 in patients who received POMALYST + Low-dose Dex, neutropenia was the most frequently reported Grade 3/4 adverse reaction, followed by anemia and thrombocytopenia. Neutropenia of any grade was reported in 51% of patients in both trials. The rate of Grade 3/4 neutropenia was 46%. The rate of febrile neutropenia was 8%.

Monitor patients for hematologic toxicities, especially neutropenia. Monitor complete blood counts weekly for the first 8 weeks and monthly thereafter. Patients may require dose interruption and/or modification [see Dosage and Administration (2.2)].

5.5 Hepatotoxicity

Hepatic failure, including fatal cases, has occurred in patients treated with POMALYST. Elevated levels of alanine aminotransferase and bilirubin have also been observed in patients treated with POMALYST. Monitor liver function tests monthly. Stop POMALYST upon elevation of liver enzymes and evaluate. After return to baseline values, treatment at a lower dose may be considered.

5.6 Hypersensitivity Reactions

Angioedema and severe dermatologic reactions have been reported. Discontinue POMALYST for angioedema, skin exfoliation, bullae, or any other severe dermatologic reactions, and do not resume therapy [see Dosage and Administration (2.2)].

5.7 Dizziness and Confusional State

In trials 1 and 2 in patients who received POMALYST + Low-dose Dex, 14% of patients experienced dizziness and 7% of patients experienced a confusional state; 1% of patients experienced Grade 3 or 4 dizziness, and 3% of patients experienced Grade 3 or 4 confusional state. Instruct patients to avoid situations where dizziness or confusional state may be a problem and not to take other medications that may cause dizziness or confusional state without adequate medical advice.

5.8 Neuropathy

In trials 1 and 2 in patients who received POMALYST + Low-dose Dex, 18% of patients experienced neuropathy, with approximately 12% of the patients experiencing peripheral neuropathy. Two percent of patients experienced Grade 3 neuropathy in trial 2. There were no cases of Grade 4 neuropathy adverse reactions reported in either trial.

5.9 Risk of Second Primary Malignancies

Cases of acute myelogenous leukemia have been reported in patients receiving POMALYST as an investigational therapy outside of multiple myeloma.

5.10 Tumor Lysis Syndrome

Tumor lysis syndrome (TLS) may occur in patients treated with pomalidomide. Patients at risk for TLS are those with high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.

6 ADVERSE REACTIONS

The following adverse reactions are described in detail in other labeling sections:

6.1 Clinical Trials Experience

Multiple Myeloma

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In Trial 1, data were evaluated from 219 patients (safety population) who received treatment with POMALYST + Low-dose Dex (112 patients) or POMALYST alone (107 patients). Median number of treatment cycles was 5. Sixty-seven percent of patients in the study had a dose interruption of either drug due to adverse reactions. Forty-two percent of patients in the study had a dose reduction of either drug due to adverse reactions. The discontinuation rate due to adverse reactions was 11%.

In Trial 2, data were evaluated from 450 patients (safety population) who received treatment with POMALYST + Low-dose Dex (300 patients) or High-dose Dexamethasone (High-dose Dex) (150 patients). The median number of treatment cycles for the POMALYST + Low-dose Dex arm was 5. In the POMALYST + Low-dose Dex arm, 67% of patients had a dose interruption of POMALYST, the median time to the first dose interruption of POMALYST was 4.1 weeks. Twenty-seven percent of patients had a dose reduction of POMALYST, the median time to the first dose reduction of POMALYST was 4.5 weeks. Eight percent of patients discontinued POMALYST due to adverse reactions.

Tables 2 and 3 summarize the adverse reactions reported in Trials 1 and 2, respectively.

Table 2: Adverse Reactions in Any POMALYST Treatment Arm in Trial 1*
* Regardless of attribution of relatedness to POMALYST.
a POMALYST alone arm includes all patients randomized to the POMALYST alone arm who took study drug; 61 of the 107 patients had dexamethasone added during the treatment period.
b Serious adverse reactions were reported in at least 2 patients in any POMALYST treatment arm.
Data cutoff: 01 March 2013
All Adverse Reactions ≥10% in
Either Arm
Grade 3 or 4 ≥5% in Either Arm
System Organ Class/Preferred Term
POMALYSTa
(N=107)
POMALYST +
Low-dose Dex
(N=112)

POMALYST
(N=107)
POMALYST +
Low-dose Dex
(N=112)
Number (%) of patients with at least one adverse reaction 107 (100) 112 (100) 98 (91.6) 102 (91.1)
Blood and lymphatic system disorders
     Neutropenia b 57 (53.3) 55 (49.1) 51 (47.7) 46 (41.1)
     Anemia b 41 (38.3) 47 (42.0) 25 (23.4) 24 (21.4)
     Thrombocytopenia b 28 (26.2) 26 (23.2) 24 (22.4) 21 (18.8)
     Leukopenia 14 (13.1) 22 (19.6) 7 (6.5) 11 (9.8)
     Febrile neutropenia b <10% <10% 6 (5.6) 3 (2.7)
     Lymphopenia 4 (3.7) 17 (15.2) 2 (1.9) 8 (7.1)
General disorders and administration site conditions
     Fatigue and asthenia b 62 (57.9) 70 (62.5) 13 (12.1) 19 (17.0)
     Edema peripheral 27 (25.2) 19 (17.0) 0 (0.0) 0 (0.0)
     Pyrexia b 25 (23.4) 36 (32.1) <5% <5%
     Chills 11 (10.3) 14 (12.5) 0 (0.0) 0 (0.0)
Gastrointestinal disorders
     Nausea b 39 (36.4) 27 (24.1) <5% <5%
     Constipation b 38 (35.5) 41 (36.6) <5% <5%
     Diarrhea 37 (34.6) 40 (35.7) <5% <5%
     Vomiting b 15 (14.0) 16 (14.3) <5% 0 (0.0)
Musculoskeletal and connective tissue disorders
     Back pain b 37 (34.6) 36 (32.1) 15 (14.0) 11 (9.8)
     Musculoskeletal chest pain 25 (23.4) 22 (19.6) <5% 0 (0.0)
     Muscle spasms 23 (21.5) 22 (19.6) <5% <5%
     Arthralgia 18 (16.8) 17 (15.2) <5% <5%
     Muscular weakness 15 (14.0) 15 (13.4) 6 (5.6) 4 (3.6)
     Bone pain 13 (12.1) 8 (7.1) <5% <5%
     Musculoskeletal pain 13 (12.1) 19 (17.0) <5% <5%
     Pain in extremity 8 (7.5) 16 (14.3) 0 (0.0) <5%
Infections and infestations
     Upper respiratory tract infection 40 (37.4) 32 (28.6) <5% <5%
     Pneumonia b 30 (28.0) 38 (33.9) 21 (19.6) 32 (28.6)
     Urinary tract infection b 11 (10.3) 19 (17.0) 2 (1.9) 10 (8.9)
     Sepsis b <10% <10% 6 (5.6) 5 (4.5)
Metabolism and nutrition disorders
     Decreased appetite 25 (23.4) 21 (18.8) <5% 0 (0.0)
     Hypercalcemia b 23 (21.5) 13 (11.6) 11 (10.3) 1 (0.9)
     Hypokalemia 13 (12.1) 13 (11.6) <5% <5%
     Hyperglycemia 12 (11.2) 17 (15.2) <5% <5%
     Hyponatremia 12 (11.2) 14 (12.5) <5% <5%
     Dehydration b <10% <10% 5 (4.7) 6 (5.4)
     Hypocalcemia 6 (5.6) 13 (11.6) 0 (0.0) <5%
Respiratory, thoracic and mediastinal disorders
     Dyspnea b 38 (35.5) 50 (44.6) 8 (7.5) 14 (12.5)
     Cough 18 (16.8) 25 (22.3) 0 (0.0) 0 (0.0)
     Epistaxis 18 (16.8) 12 (10.7) <5% 0 (0.0)
     Productive cough 10 (9.3) 14 (12.5) 0 (0.0) 0 (0.0)
     Oropharyngeal pain 6 (5.6) 12 (10.7) 0 (0.0) 0 (0.0)
Nervous system disorders
     Dizziness 24 (22.4) 20 (17.9) <5% <5%
     Peripheral neuropathy 23 (21.5) 20 (17.9) 0 (0.0) 0 (0.0)
     Headache 16 (15.0) 15 (13.4) 0 (0.0) <5%
     Tremor 11 (10.3) 15 (13.4) 0 (0.0) 0 (0.0)
Skin and subcutaneous tissue disorders
     Rash 22 (20.6) 18 (16.1) 0 (0.0) <5%
     Pruritus 16 (15.0) 10 (8.9) 0 (0.0) 0 (0.0)
     Dry skin 10 (9.3) 12 (10.7) 0 (0.0) 0 (0.0)
     Hyperhidrosis 8 (7.5) 18 (16.1) 0 (0.0) 0 (0.0)
     Night sweats 5 (4.7) 14 (12.5) 0 (0.0) 0 (0.0)
Investigations
     Blood creatinine increased b 20 (18.7) 11 (9.8) 6 (5.6) 3 (2.7)
     Weight decreased 16 (15.0) 10 (8.9) 0 (0.0) 0 (0.0)
     Weight increased 1 (0.9) 12 (10.7) 0 (0.0) 0 (0.0)
Psychiatric disorders
     Anxiety 14 (13.1) 8 (7.1) 0 (0.0) 0 (0.0)
     Confusional state b 13 (12.1) 15 (13.4) 6 (5.6) 3 (2.7)
     Insomnia 7 (6.5) 18 (16.1) 0 (0.0) 0 (0.0)
Renal and urinary disorders
     Renal failure b 16 (15.0) 11 (9.8) 9 (8.4) 8 (7.1)
Table 3: Adverse Reactions in Trial 2
a Percentage did not meet the criteria to be considered as an adverse reaction for POMALYST for that category of event (i.e., all adverse events or Grade 3 or 4 adverse events).
b Serious adverse reactions were reported in at least 3 patients in the POM + Low-dose Dex arm, AND at least 1% higher than the High-dose-Dex arm percentage.
Data cutoff: 01 March 2013
All Adverse Reactions
(≥5% in POMALYST + Low-dose
Dex arm, and at least 2% point
higher than the High-dose-Dex arm)
Grade 3 or 4
(≥1% in POMALYST + Low-dose Dex
arm, and at least 1% point higher than
the High-dose-Dex arm)
System Organ Class/Preferred Term
POMALYST +
Low-dose Dex
(N=300)
High-dose Dex
(N=150)

POMALYST +
Low-dose Dex
(N=300)
High-dose Dex
(N=150)
Number (%) of patients with at least one adverse reaction 297 (99.0) 149 (99.3) 259 (86.3) 127 (84.7)
Blood and lymphatic system disorders
     Neutropenia b 154 (51.3) 31 (20.7) 145 (48.3) 24 (16.0)
     Thrombocytopenia 89 (29.7) a 44 (29.3) a 66 (22.0) a 39 (26.0) a
     Leukopenia 38 (12.7) 8 (5.3) 27 (9.0) 5 (3.3)
     Febrile neutropenia b 28 (9.3) 0 (0.0) 28 (9.3) 0 (0.0)
General disorders and administration site conditions
     Fatigue and asthenia 140 (46.7) 64 (42.7) 26 (8.7) a 18 (12.0) a
     Pyrexia b 80 (26.7) 35 (23.3) 9 (3.0) a 7 (4.7) a
     Edema peripheral 52 (17.3) 17 (11.3) 4 (1.3) a 3 (2.0) a
     Pain 11 (3.7) a 3 (2.0) a 5 (1.7) 1 (0.7)
Infections and infestations
     Upper respiratory tract infection b 93 (31.0) 19 (12.7) 9 (3.0) 1 (0.7)
     Pneumonia b 58 (19.3) 20 (13.3) 47 (15.7) 15 (10.0)
     Neutropenic sepsis b 3 (1.0) a 0 (0.0) a 3 (1.0) 0 (0.0)
Gastrointestinal disorders
     Diarrhea 66 (22.0) 28 (18.7) 3 (1.0) a 2 (1.3) a
     Constipation 65 (21.7) 22 (14.7) 7 (2.3) 0 (0.0)
     Nausea 45 (15.0) 17 (11.3) 3 (1.0) a 2 (1.3) a
     Vomiting 23 (7.7) 6 (4.0) 3 (1.0) 0 (0.0)
Musculoskeletal and connective tissue disorders
     Back pain b 59 (19.7) 24 (16.0) 15 (5.0) 6 (4.0)
     Bone pain b 54 (18.0) 21 (14.0) 22 (7.3) 7 (4.7)
     Muscle spasms 46 (15.3) 11 (7.3) 1 (0.3) a 1 (0.7) a
     Arthralgia 26 (8.7) 7 (4.7) 2 (0.7) a 1 (0.7) a
     Pain in extremity 20 (6.7) a 9 (6.0) a 6 (2.0) 0 (0.0)
Respiratory, thoracic and mediastinal disorders
     Dyspnea b 76 (25.3) 25 (16.7) 17 (5.7) 7 (4.7)
     Cough 60 (20.0) 15 (10.0) 2 (0.7) a 1 (0.7) a
     Chronic obstructive pulmonary disease b 5 (1.7) a 0 (0.0) a 4 (1.3) 0 (0.0)
Nervous system disorders
     Peripheral neuropathy 52 (17.3) 18 (12.0) 5 (1.7) a 2 (1.3) a
     Dizziness 37 (12.3) 14 (9.3) 4 (1.3) a 2 (1.3) a
     Headache 23 (7.7) 8 (5.3) 1 (0.3) a 0 (0.0) a
     Tremor 17 (5.7) 2 (1.3) 2 (0.7) a 0 (0.0) a
     Depressed level of consciousness 5 (1.7) a 0 (0.0) a 3 (1.0) 0 (0.0)
Metabolism and nutrition disorders
     Decreased appetite 38 (12.7) 12 (8.0) 3 (1.0) a 2 (1.3) a
     Hypokalemia 28 (9.3) a 12 (8.0) a 12 (4.0) 4 (2.7)
     Hypocalcemia 12 (4.0) a 9 (6.0) a 5 (1.7) 1 (0.7)
Skin and subcutaneous tissue disorders
     Rash 23 (7.7) 2 (1.3) 3 (1.0) 0 (0.0)
     Pruritus 22 (7.3) 5 (3.3) 0 (0.0) a 0 (0.0) a
     Hyperhidrosis 15 (5.0) 1 (0.7) 0 (0.0) a 0 (0.0) a
Investigations
     Neutrophil count decreased 15 (5.0) 1 (0.7) 14 (4.7) 1 (0.7)
     Platelet count decreased 10 (3.3) a 3 (2.0) a 8 (2.7) 2 (1.3)
     White blood cell count decreased 8 (2.7) a 1 (0.7) a 8 (2.7) 0 (0.0)
     Alanine aminotransferase increased 7 (2.3) a 2 (1.3) a 5 (1.7) 0 (0.0)
     Aspartate aminotransferase increased 4 (1.3) a 2 (1.3) a 3 (1.0) 0 (0.0)
     Lymphocyte count decreased 3 (1.0) a 1 (0.7) a 3 (1.0) 0 (0.0)
Renal and urinary disorders
     Renal failure 31 (10.3) a 18 (12.0) a 19 (6.3) 8 (5.3)
Injury, poisoning and procedural complications
     Femur fracture b 5 (1.7) a 1 (0.7) a 5 (1.7) 1 (0.7)
Reproductive system and breast disorders
     Pelvic pain 6 (2.0) a 3 (2.0) a 4 (1.3) 0 (0.0)

Other Adverse Reactions
Other adverse reactions of POMALYST in patients with multiple myeloma, not described above, and considered important:

Cardiac disorders: Myocardial infarction, Atrial fibrillation, Angina pectoris, Cardiac failure congestive
Ear and labyrinth disorders: Vertigo
Gastrointestinal disorders: Abdominal pain
General disorders and administration site conditions: General physical health deterioration, Non-cardiac chest pain, Multi-organ failure
Hepatobiliary disorders: Hyperbilirubinemia
Infections and infestations: Pneumocystis jiroveci pneumonia, Respiratory syncytial virus infection, Neutropenic sepsis, Bacteremia, Pneumonia respiratory syncytial viral, Cellulitis, Urosepsis, Septic shock, Clostridium difficile colitis, Pneumonia streptococcal, Lobar pneumonia, Viral infection, Lung infection
Investigations: Alanine aminotransferase increased, Hemoglobin decreased
Injury, poisoning and procedural complications: Fall, Compression fracture, Spinal compression fracture
Metabolism and nutritional disorders: Hyperkalemia, Failure to thrive
Nervous System disorders: Depressed level of consciousness, Syncope
Psychiatric disorders: Mental status change
Renal and urinary disorders: Urinary retention, Hyponatremia
Reproductive system and breast disorders: Pelvic pain
Respiratory, thoracic, and mediastinal disorders: Interstitial lung disease, Pulmonary embolism, Respiratory failure, Bronchospasm
Vascular disorders: Hypotension

6.2 Postmarketing Experience

The following adverse drug reactions have been identified from the worldwide postmarketing experience with POMALYST: Pancytopenia, tumor lysis syndrome, allergic reactions (e.g., angioedema, urticaria), elevated liver enzymes, hepatic failure (including fatal cases).

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

7 DRUG INTERACTIONS

Pomalidomide is primarily metabolized by CYP1A2 and CYP3A. Pomalidomide is also a substrate for P-glycoprotein (P-gp).

7.1 Drugs That May Increase Pomalidomide Plasma Concentrations

CYP1A2 inhibitors: Pomalidomide exposure is increased when POMALYST is co-administered with a strong CYP1A2 inhibitor (fluvoxamine) in the presence of a strong CYP3A4/5 and P-gp inhibitor (ketoconazole). Ketoconazole in the absence of a CYP1A2 inhibitor does not increase pomalidomide exposure. Avoid co-administration of strong CYP1A2 inhibitors (e.g. ciprofloxacin and fluvoxamine) [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)]. If it is medically necessary to co-administer strong inhibitors of CYP1A2 in the presence of strong inhibitors of CYP3A4 and P-gp, POMALYST dose should be reduced by 50%.

The effect of a CYP1A2 inhibitor in the absence of a co-administered CYP3A4 and P-gp inhibitor has not been studied. Monitor for toxicities if CYP1A2 inhibitors are to be co-administered in the absence of a co-administered CYP3A4 and P-gp inhibitor, and reduce dose if needed.

7.2 Drugs That May Decrease Pomalidomide Plasma Concentrations

Smoking: Cigarette smoking may reduce pomalidomide exposure due to CYP1A2 induction. Patients should be advised that smoking may reduce the efficacy of pomalidomide.

CYP1A2 inducers: Co-administration of POMALYST with drugs that are CYP1A2 inducers has not been studied and may reduce pomalidomide exposure.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category X [see Boxed Warnings and Contraindications (4)]

Risk Summary

POMALYST can cause embryo-fetal harm when administered to a pregnant female and is contraindicated during pregnancy. POMALYST is a thalidomide analogue.

Thalidomide is a human teratogen, inducing a high frequency of severe and life-threatening birth defects such as amelia (absence of limbs), phocomelia (short limbs), hypoplasticity of the bones, absence of bones, external ear abnormalities (including anotia, micropinna, small or absent external auditory canals), facial palsy, eye abnormalities (anophthalmos, microphthalmos), and congenital heart defects. Alimentary tract, urinary tract, and genital malformations have also been documented and mortality at or shortly after birth has been reported in about 40% of infants.

Pomalidomide was teratogenic in both rats and rabbits when administered during the period of organogenesis. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

If pregnancy does occur during treatment, immediately discontinue the drug. Under these conditions, refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling. Report any suspected fetal exposure to POMALYST to the FDA via the MedWatch program at 1-800-FDA-1088 and also to Celgene Corporation at 1-888-423-5436.

Animal Data

Pomalidomide was teratogenic in both rats and rabbits in the embryo-fetal developmental studies when administered during the period of organogenesis.

In rats, pomalidomide was administered orally to pregnant animals at doses of 25 to 1000 mg/kg/day. Malformations or absence of urinary bladder, absence of thyroid gland, and fusion and misalignment of lumbar and thoracic vertebral elements (vertebral, central, and/or neural arches) were observed at all dose levels. There was no maternal toxicity observed in this study. The lowest dose in rats resulted in an exposure (AUC) approximately 85-fold of the human exposure at the recommended dose of 4 mg/day. Other embryo-fetal toxicities included increased resorptions leading to decreased number of viable fetuses.

In rabbits, pomalidomide was administered orally to pregnant animals at doses of 10 to 250 mg/kg/day. Increased cardiac malformations such as interventricular septal defect were seen at all doses with significant increases at 250 mg/kg/day. Additional malformations observed at 250 mg/kg/day included anomalies in limbs (flexed and/or rotated fore- and/or hindlimbs, unattached or absent digit) and associated skeletal malformations (not ossified metacarpal, misaligned phalanx and metacarpal, absent digit, not ossified phalanx, and short not ossified or bent tibia), moderate dilation of the lateral ventricle in the brain, abnormal placement of the right subclavian artery, absent intermediate lobe in the lungs, low-set kidney, altered liver morphology, incompletely or not ossified pelvis, an increased average for supernumerary thoracic ribs, and a reduced average for ossified tarsals. No maternal toxicity was observed at the low dose (10 mg/kg/day) that resulted in cardiac anomalies in fetuses; this dose resulted in an exposure (AUC) approximately equal to that reported in humans at the recommended dose of 4 mg/day. Additional embryo-fetal toxicity included increased resorption.

8.3 Nursing Mothers

It is not known if pomalidomide is excreted in human milk. Pomalidomide was excreted in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from POMALYST, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness of POMALYST in patients below the age of 18 years have not been established.

8.5 Geriatric Use

No dosage adjustment is required for POMALYST based on age.

Of the total number of patients in clinical studies of POMALYST, 44% were aged older than 65 years, while 10% were aged older than 75 years. No overall differences in effectiveness were observed between these patients and younger patients. In these studies, patients older than 65 years were more likely than patients less than or equal to 65 years of age to experience pneumonia.

8.6 Females of Reproductive Potential and Males

POMALYST can cause fetal harm when administered during pregnancy [see Use in Specific Populations (8.1)]. Females of reproductive potential must avoid pregnancy while taking POMALYST and for at least 4 weeks after completing therapy.

Females
Females of reproductive potential must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control simultaneously: one highly effective form of contraception – tubal ligation, IUD, hormonal (birth control pills, injections, hormonal patches, vaginal rings, or implants), or partner’s vasectomy, and 1 additional effective contraceptive method – male latex or synthetic condom, diaphragm, or cervical cap. Contraception must begin 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy. Females of reproductive potential should be referred to a qualified provider of contraceptive methods, if needed.

Females of reproductive potential must have 2 negative pregnancy tests before initiating POMALYST. The first test should be performed within 10-14 days, and the second test within 24 hours prior to prescribing POMALYST. Once treatment has started and during dose interruptions, pregnancy testing for females of reproductive potential should occur weekly during the first 4 weeks of use, then pregnancy testing should be repeated every 4 weeks in females with regular menstrual cycles. If menstrual cycles are irregular, the pregnancy testing should occur every 2 weeks. Pregnancy testing and counseling should be performed if a patient misses her period or if there is any abnormality in her menstrual bleeding. POMALYST treatment must be discontinued during this evaluation.

Males
Pomalidomide is present in the semen of males who take POMALYST. Therefore, males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking POMALYST and for up to 28 days after discontinuing POMALYST, even if they have undergone a successful vasectomy. Male patients taking POMALYST must not donate sperm.

8.7 Renal Impairment

Pomalidomide and its metabolites are primarily excreted by the kidneys [see Clinical Pharmacology (12.3)]. The influence of renal impairment on the safety, efficacy, and pharmacokinetics of pomalidomide has not been evaluated. Patients with serum creatinine greater than 3.0 mg/dL were excluded in clinical studies. Avoid POMALYST in patients with a serum creatinine greater than 3.0 mg/dL.

8.8 Hepatic Impairment

Pomalidomide is metabolized in the liver [see Clinical Pharmacology (12.3)]. The influence of hepatic impairment on the safety, efficacy, and pharmacokinetics of pomalidomide has not been evaluated. Patients with serum bilirubin greater than 2.0 mg/dL and AST/ALT greater than 3.0 x upper limit normal (ULN) were excluded in clinical studies. Avoid POMALYST in patients with serum bilirubin greater than 2.0 mg/dL and AST/ALT greater than 3.0 x ULN.

10 OVERDOSAGE

No specific information is available on the treatment of overdose with pomalidomide, and it is unknown whether pomalidomide or its metabolites are dialyzable.

11 DESCRIPTION

POMALYST is an immunomodulatory antineoplastic agent. The chemical name is (RS)-4-Amino-2-(2,6-dioxo-piperidin-3-yl)-isoindoline-1,3-dione and it has the following chemical structure:

Pomalidomide Chemical Structure

The empirical formula for pomalidomide is C13H11N3O4 and the gram molecular weight is 273.24.

Pomalidomide is a yellow solid powder.  It has limited to low solubility into organic solvents and it has low solubility in all pH solutions (about 0.01 mg/mL).  Pomalidomide has a chiral carbon atom which exists as a racemic mixture of the R(+) and S(-) enantiomers.

POMALYST is available in 1-mg, 2-mg, 3-mg, and 4-mg capsules for oral administration. Each capsule contains pomalidomide as the active ingredient and the following inactive ingredients: mannitol, pregelatinized starch, and sodium stearyl fumarate. The 1-mg capsule shell contains gelatin, titanium dioxide, FD&C blue 2, yellow iron oxide, white ink, and black ink. The 2-mg capsule shell contains gelatin, titanium dioxide, FD&C blue 2, yellow iron oxide, FD&C red 3, and white ink. The 3-mg capsule shell contains gelatin, titanium dioxide, FD&C blue 2, yellow iron oxide, and white ink. The 4-mg capsule shell contains gelatin, titanium dioxide, FD&C blue 1, FD&C blue 2, and white ink.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Pomalidomide, an analogue of thalidomide, is an immunomodulatory agent with antineoplastic activity. In in vitro cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells. Additionally, pomalidomide inhibited the proliferation of lenalidomide-resistant multiple myeloma cell lines and synergized with dexamethasone in both lenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumor cell apoptosis. Pomalidomide enhanced T cell- and natural killer (NK) cell-mediated immunity and inhibited production of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. Pomalidomide demonstrated anti-angiogenic activity in a mouse tumor model and in the in vitro umbilical cord model.

12.2 Pharmacodynamics

The QTc prolongation potential of pomalidomide was evaluated in a single center, randomized, double-blind crossover study (N=72) using 4 mg pomalidomide, 20 mg pomalidomide, placebo, and 400 mg moxifloxacin (positive control). No significant QTc prolongation effect of pomalidomide was observed following pomalidomide doses of 4 and 20 mg.

12.3 Pharmacokinetics

Absorption
Following administration of single oral doses of POMALYST, the maximum plasma concentration (Cmax) for pomalidomide occurs at 2 and 3 hours postdose. The systemic exposure (AUC) of pomalidomide increases in an approximately dose proportional manner.

In patients with multiple myeloma who received POMALYST 4 mg daily alone or in combination with dexamethasone, pomalidomide steady-state drug exposure was characterized by AUC(Τ) of 400 ng•h/mL and Cmax of 75 ng/mL. Following multiple doses, pomalidomide has an accumulation ratio of 27% to 31%.

Distribution
Pomalidomide has a mean apparent volume of distribution (Vd/F) between 62 and 138 L at steady state. Pomalidomide is distributed in semen of healthy subjects at a concentration of approximately 67% of plasma level at 4 hours postdose (~Tmax) after 4 days of once-daily dosing at 2 mg. Human plasma protein binding ranges from 12% to 44% and is not concentration dependent. Pomalidomide is a substrate for P-glycoprotein (P-gp).

Metabolism
Pomalidomide is primarily metabolized in the liver by CYP1A2 and CYP3A4. In vitro, CYP1A2 and CYP3A4 were identified as the primary enzymes involved in the CYP-mediated hydroxylation of pomalidomide, with additional minor contributions from CYP2C19 and CYP2D6.

Elimination
Pomalidomide is eliminated with a median plasma half-life of approximately 9.5 hours in healthy subjects and approximately 7.5 hours in patients with multiple myeloma. Pomalidomide has a mean total body clearance (CL/F) of 7-10 L/h.

Following a single oral administration of [14C]-pomalidomide (2 mg) to healthy subjects, approximately 73% and 15% of the radioactive dose was eliminated in urine and feces, respectively, with approximately 2% and 8% of the radiolabeled dose eliminated unchanged as pomalidomide in urine and feces.

Drug Interactions

Drugs that Inhibit Pomalidomide Metabolism

CYP1A2 Inhibitors: The effect of CYP1A2 inhibitors, in the absence of a co-administered CYP3A4 and P-gp inhibitor, is unknown. However, co-administration of fluvoxamine (a strong CYP1A2 inhibitor) in the presence of ketoconazole (a strong CYP3A4 and P-gp inhibitor) to 12 healthy male subjects increased exposure (geometric mean AUCINF) to pomalidomide by 146% compared to pomalidomide administered alone [see Dosage and Administration (2.2) and Drug Interactions (7.1)].

Strong CYP3A4 and P-glycoprotein (P-gp) Inhibitors: Co-administration of ketoconazole (a strong CYP3A4 and P-gp inhibitor) in 16 healthy male subjects resulted in an increased exposure (geometric mean AUCINF) to pomalidomide of 19% compared to pomalidomide administered alone.

Drugs that Induce Pomalidomide Metabolism

Strong CYP1A2 Inducers: Co-administration of POMALYST with drugs that are CYP1A2 inducers has not been studied and may reduce pomalidomide exposure.

Strong CYP3A4 Inducers: Co-administration of carbamazepine to 16 healthy male subjects decreased exposure (geometric mean AUCINF) to pomalidomide by 21% compared to pomalidomide administered alone.

Dexamethasone: Co-administration of multiple doses of 4 mg POMALYST with 20 mg to 40 mg dexamethasone (a weak to moderate inducer of CYP3A4) to patients with multiple myeloma had no effect on the pharmacokinetics of pomalidomide compared with pomalidomide administered alone.

In Vitro Inhibition of Drug Metabolizing Enzymes and Transporters by Pomalidomide

Pomalidomide does not inhibit or induce CYP450 enzymes or transporters in vitro.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies examining the carcinogenic potential of pomalidomide have not been conducted. One of 12 monkeys dosed with 1 mg/kg of pomalidomide (an exposure approximately 15-fold of the exposure in patients at the recommended dose of 4 mg/day) developed acute myeloid leukemia in a 9-month repeat-dose toxicology study.

Pomalidomide was not mutagenic or clastogenic in a battery of tests, including the bacteria reverse mutation assay (Ames test), the in vitro assay using human peripheral blood lymphocytes, and the micronucleus test in orally treated rats administered doses up to 2000 mg/kg/day.

In a fertility and early embryonic development study in rats, drug-treated males were mated with untreated or treated females. Pomalidomide was administered to males and females at doses of 25 to 1000 mg/kg/day. When treated males were mated with treated females, there was an increase in post-implantation loss and a decrease in mean number of viable embryos at all dose levels. There were no other effects on reproductive functions or the number of pregnancies. The lowest dose tested in animals resulted in an exposure (AUC) approximately 100-fold of the exposure in patients at the recommended dose of 4 mg/day. When treated males in this study were mated with untreated females, all uterine parameters were comparable to the controls. Based on these results, the observed effects were attributed to the treatment of females.

14 CLINICAL STUDIES

14.1 Multiple Myeloma

Trial 1 was a phase 2, multicenter, randomized open-label study in patients with relapsed multiple myeloma who were refractory to their last myeloma therapy and had received lenalidomide and bortezomib. Patients were considered relapsed if they had achieved at least stable disease for at least 1 cycle of treatment to at least 1 prior regimen and then developed progressive disease. Patients were considered refractory if they experienced disease progression on or within 60 days of their last therapy. A total of 221 patients were randomized to receive POMALYST alone or POMALYST with Low-dose Dex. In Trial 1, the safety and efficacy of POMALYST 4 mg, once daily for 21 of 28 days, until disease progression, were evaluated alone and in combination with Low-dose Dex (40 mg/day given only on Days 1, 8, 15, and 22 of each 28-day cycle for patients aged 75 years or younger, or 20 mg/day given only on Days 1, 8, 15, and 22 of each 28-day cycle for patients aged greater than 75 years). Patients in the POMALYST alone arm were allowed to add Low-dose Dex upon disease progression.

Table 4 summarizes the baseline patient and disease characteristics in Trial 1. The baseline demographics and disease characteristics were balanced and comparable between the study arms.

Table 4: Baseline Demographic and Disease-Related Characteristics – Trial 1
Data cutoff: 01 April 2011
     
POMALYST
  (n=108)
  POMALYST
+ Low-dose
Dex
  (n=113)
  Patient Characteristics
  Median age, years (range)   61 (37-88)   64 (34-88)
  Age distribution, n (%)
     <65 years
     ≥65 years
 
  65 (60.2)
  43 (39.8)
 
  60 (53.1)
  53 (46.9)
  Sex, n (%)
    Male
    Female

  57 (52.8)
  51 (47.2)

  62 (54.9)
  51 (45.1)
  Race/ethnicity, n (%)
    White
    Black or African American
    All other race
 
  86 (79.6)
  16 (14.8)
  6 (5.6)
 
  92 (81.4)
  17 (15)
  4 (3.6)
  ECOG Performance, n (%)
  Status 0-1
 
  95 (87.9)
 
  100 (88.5)
  Disease Characteristics
  Number of prior therapies
    Median, (min, max)
 
  5 (2, 12)
 
  5 (2, 13)
  Prior transplant, n (%)   82 (75.9)   84 (74.3)
  Refractory to bortezomib
  and lenalidomide, n (%)
  64 (59.3)   69 (61.1)

Table 5 summarizes the analysis results of overall response rate (ORR) and duration of response (DOR), based on assessments by the Independent Review Adjudication Committee for the treatment arms in Trial 1. ORR did not differ based on type of prior antimyeloma therapy.

Table 5: Trial 1 Results
a Results are prior to the addition of dexamethasone.
b ORR = PR + CR per EBMT criteria.
CI, confidence interval; NE, not established (the median has not yet been reached).
Data cutoff: 01 April 2011
     POMALYST a
  (n=108)
  POMALYST +
  Low-dose Dex
  (n=113)
  Response
  Overall Response Rate
  (ORR),b n (%)
  8 (7.4)   33 (29.2)
  95% CI for ORR (%)   (3.3, 14.1)   (21.0, 38.5)
  Complete Response (CR), n (%)   0 (0.0)   1 (0.9)
  Partial Response (PR), n (%)   8 (7.4)   32 (28.3)
  Duration of Response (DOR)      
  Median, months   NE   7.4
  95% CI for DOR (months)   NE   (5.1, 9.2)

Trial 2 was a Phase 3 multi-center, randomized, open-label study, where POMALYST + Low-dose Dex therapy was compared to High-dose Dex in adult patients with relapsed and refractory multiple myeloma, who had received at least two prior treatment regimens, including lenalidomide and bortezomib, and demonstrated disease progression on or within 60 days of the last therapy. Patients with creatinine clearance ≥ 45mL/min qualified for the trial. A total of 455 patients were enrolled in the trial: 302 in the POMALYST + Low-dose Dex arm and 153 in the High-dose Dex arm. Patients in the POMALYST + Low-dose Dex arm were administered 4 mg POMALYST orally on Days 1 to 21 of each 28-day cycle. Dexamethasone (40 mg) was administered once per day on Days 1, 8, 15 and 22 of a 28-day cycle. Patients > 75 years of age started treatment with 20 mg dexamethasone using the same schedule. For the High-dose Dex arm, dexamethasone (40 mg) was administered once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle. Patients > 75 years of age started treatment with 20 mg dexamethasone using the same schedule. Treatment continued until patients had disease progression.

Baseline patient and disease characteristics were balanced and comparable between the study arms, as summarized in Table 6. Overall, 94% of patients had disease refractory to lenalidomide, 79% had disease refractory to bortezomib and 74% had disease refractory to both lenalidomide and bortezomib.

Table 6: Baseline Demographic and Disease-Related Characteristics – Trial 2
Data cutoff: 01March 2013
  POMALYST + Low-dose Dex
(N=302)
High-dose Dex
 
(N=153)
Patient Characteristics
Median Age, years (range) 64 (35, 84) 65 (35, 87)
Age Distribution n (%)
< 65 years
≥ 65 years
 
158 (52)
144 (48)
 
74 (48)
79 (52)
Sex n (%)
Male
Female
 
181 (60)
121 (40)
 
87 (57)
66 (43)
Race/Ethnicity n (%)
White
Black or African American
Asian
Other Race
Not Collected
 
244 (81)
4 (1)
4 (1)
2 (1)
48 (16)
 
113 (74)
3 (2)
0 (0)
2 (1)
35 (23)
ECOG Performance n (%)
Status 0
Status 1
Status 2
Status 3
Missing
 
110 (36)
138 (46)
52 (17)
0 (0)
2 (1)
 
36 (24)
86 (56)
25 (16)
3 (2)
3 (2)
Disease Characteristics
Number of Prior Therapies
Median, (Min, Max)
 
5 (2, 14)
 
5 (2, 17)
Prior stem cell transplant n (%) 214 (71) 105 (69)
Refractory to bortezomib and lenalidomide n (%) 225 (75) 113 (74)

Table 7 summarizes the progression free survival (PFS) and overall response rate (ORR) based on the assessment by the Independent Review Adjudication Committee (IRAC) review at the final PFS analysis and overall survival (OS) at the OS analysis. PFS was significantly longer with POMALYST + Low-dose Dex than High-dose Dex: HR 0.45 (95% CI: 0.35-0.59 p < 0.001). OS was also significantly longer with POMALYST + Low-dose Dex than High-dose Dex: HR 0.70 (95% CI: 0.54-0.92 p = 0.009).The Kaplan-Meier curves for PFS and OS for the ITT population are provided in Figures 1 and 2, respectively.

Table 7: Trial 2 Results
Note: CI=Confidence interval; HD-Dex=High dose dexamethasone; IRAC=Independent Review Adjudication Committee; LD-Dex=Low dose dexamethasone.
a The median is based on Kaplan-Meier estimate.
b Based on Cox proportional hazards model comparing the hazard functions associated with treatment groups, stratified by age (≤75 vs >75), diseases population (refractory to both Lenalidomide and Bortezomib vs not refractory to both drugs), and prior number of antimyeloma therapy (=2 vs >2), stratification factors for the trial.
c The p-value is based on a stratified log-rank test with the same stratification factors as the above Cox model.
d 53% of patients in the High-dose Dex arm subsequently received POMALYST.
e Based on Cox proportional hazards model (unstratified) comparing the hazard functions associated with treatment groups.
f The p-value is based on an unstratified log-rank test.
gAlpha control for PFS and OS.
Data cutoff: 07 Sep 2012 for PFS
Data cutoff: 01 Mar 2013 for OS and ORR
  POMALYST + Low-dose Dex
(N=302)
High-dose Dex
 
(N=153)
Progression Free Survival Time
Number (%) of events 164 (54.3) 103 (67.3)
Mediana (2-sided 95% CI) (months) 3.6 [3.0, 4.6] 1.8 [1.6, 2.1]
Hazard Ratio (Pom+LD-Dex:HD-Dex) 2-Sided 95% CIb 0.45 [0.35, 0.59]
Log-Rank Test 2-sided P-Valuec <0.001
Overall Survival Timed
Number (%) of deaths 147 (48.7) 86 (56.2)
Mediana (2-sided 95% CI) (months) 12.4 [10.4, 15.3] 8.0[6.9, 9.0]
Hazard Ratio (Pom+LD-Dex:HD-Dex) 2-Sided 95% CIe 0.70 [0.54, 0.92]
Log-Rank Test 2-sided P-Value f, g 0.009
Overall Response Rate, n (%) 71 (23.5) 6 (3.9)
  Complete Response 1 (0.3) 0
  Very Good Partial Response 8 (2.6) 1 (0.7)
  Partial Response 62 (20.5) 5 (3.3)

Figure 1: Progression Free Survival Based on IRAC Review of Response by IMWG Criteria (Stratified Log Rank Test) (ITT Population)

Progression Free Survival Based on IRAC Review of Response by IMWG Criteria

Data cut-off: 07 Sep 2012

Figure 2: Kaplan-Meier Curve of Overall Survival (ITT Population)

Kaplan-Meier Curve of Overall Survival

Data cutoff: 01 Mar 2013

15 REFERENCES

1.       OSHA Hazardous Drugs. OSHA. [Accessed on 29 January 2013, from http://www.osha.gov/SLTC/hazardousdrugs/index.html]

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Dark blue opaque cap and yellow opaque body, imprinted “POML” on the cap in white ink and “1 mg” on the body in black ink
    1 mg bottles of 21        (NDC 59572-501-21)
    1 mg bottles of 100      (NDC 59572-501-00)

Dark blue opaque cap and orange opaque body, imprinted “POML” on the cap and “2 mg” on the body in white ink
    2 mg bottles of 21        (NDC 59572-502-21)
    2 mg bottles of 100      (NDC 59572-502-00)

Dark blue opaque cap and green opaque body, imprinted “POML” on the cap and “3 mg” on the body in white ink
    3 mg bottles of 21        (NDC 59572-503-21)
    3 mg bottles of 100      (NDC 59572-503-00)

Dark blue opaque cap and blue opaque body, imprinted “POML” on the cap and “4 mg” on the body in white ink
    4 mg bottles of 21        (NDC 59572-504-21)
    4 mg bottles of 100      (NDC 59572-504-00)

16.2 Storage

Store at 20°C-25°C (68°F-77°F); excursions permitted to 15°C-30°C (59°F-86°F). [See USP Controlled Room Temperature].

16.3 Handling and Disposal

Care should be exercised in handling of POMALYST. POMALYST capsules should not be opened or crushed. If powder from POMALYST contacts the skin, wash the skin immediately and thoroughly with soap and water. If POMALYST contacts the mucous membranes, flush thoroughly with water.

Follow procedures for proper handling and disposal of anticancer drugs.1

17 PATIENT COUNSELING INFORMATION

See FDA-approved Patient Labeling (Medication Guide)

Embryo-Fetal Toxicity
Advise patients that POMALYST is contraindicated in pregnancy [see Contraindications (4)]. POMALYST is a thalidomide analogue and may cause serious birth defects or death to a developing baby [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].
  

POMALYST REMS Program
Because of the risk of embryo-fetal toxicity, POMALYST is only available through a restricted program called POMALYST REMS [see Warnings and Precautions (5.2)].  

Venous and Arterial Thromboembolism
Inform patients of the risk of developing DVT, PE, MI, and stroke and to report immediately any signs and symptoms suggestive of these events for evaluation [see Boxed Warnings and Warnings and Precautions (5.3)].

Hematologic Toxicities
Inform patients on the risks of developing neutropenia, thrombocytopenia, and anemia and the need to report signs and symptoms associated with these events to their healthcare provider for further evaluation [see Warnings and Precautions (5.4)].

Hepatotoxicity
Inform patients on the risks of developing hepatotoxicity, including hepatic failure and death, and to report signs and symptoms associated with these events to their healthcare provider for evaluation [see Warnings and Precautions (5.5)].

Hypersensitivity
Inform patients of the risk for angioedema and severe skin reactions and to report any signs and symptoms associated with these events to their healthcare provider for evaluation [see Warnings and Precautions (5.6)].

Dizziness and Confusional State
Inform patients of the potential risk of dizziness and confusional state with the drug, to avoid situations where dizziness or confusional state may be a problem, and not to take other medications that may cause dizziness or confusional state without adequate medical advice [see Warnings and Precautions (5.7)].

Neuropathy
Inform patients of the risk of neuropathy and to report the signs and symptoms associated with these events to their healthcare provider for further evaluation [see Warnings and Precautions (5.8)].

Second Primary Malignancies
Inform the patient that the potential risk of developing acute myelogenous leukemia during treatment with POMALYST is unknown [see Warnings and Precautions (5.9)].

Tumor Lysis Syndrome
Inform patients of the potential risk of tumor lysis syndrome and to report any signs and symptoms associated with this event to their healthcare provider for evaluation [see Warnings and Precautions (5.10)].

Dosing Instructions
Inform patients on how to take POMALYST [see Dosage and Administration (2.1)]

Other Information
Advise patients who smoke to stop because smoking may reduce the efficacy of pomalidomide [see Drug Interactions (7.2)].

Manufactured for:   Celgene Corporation
Summit, NJ 07901

POMALYST®, REVLIMID®, THALOMID®, and POMALYST REMS® are registered trademarks of Celgene Corporation.
Pat. http://www.celgene.com/therapies
© 2005-2015 Celgene Corporation   All rights reserved.
                                                                                                                    POMPI.004/MG.004 04/2015

MEDICATION GUIDE
POMALYST® (POM-uh-list)
(pomalidomide)
capsules

What is the most important information I should know about POMALYST?

      Men, if your female partner becomes pregnant, you should call your healthcare provider right away.

What is POMALYST?

POMALYST is a prescription medicine, taken along with the medicine dexamethasone, used to treat people with multiple myeloma who:

It is not known if POMALYST is safe and effective in people under 18 years of age.

Who should not take POMALYST?

Do not take POMALYST if you are pregnant, plan to become pregnant, or become pregnant during treatment with POMALYST. See “What is the most important information I should know about POMALYST?

What should I tell my healthcare provider before taking POMALYST?

Before you take POMALYST, tell your healthcare provider if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. POMALYST and other medicines may affect each other, causing serious side effects. Talk with your healthcare provider before taking any new medicines.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist.

How should I take POMALYST?

Take POMALYST exactly as prescribed and follow all the instructions of the POMALYST REMS program.

Before prescribing POMALYST, your healthcare provider will:

Females who can become pregnant:

Males who take POMALYST, even those who have had a vasectomy, must agree to use a latex or synthetic condom during sexual contact with a pregnant female or a female who can become pregnant.

What should I avoid while taking POMALYST?

What are the possible side effects of POMALYST?
POMALYST may cause serious side effects, including:

Your healthcare provider may tell you to stop taking POMALYST if you develop certain serious side effects during treatment.

The most common side effects of POMALYST include:

These are not all the possible side effects of POMALYST.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

How should I store POMALYST?

Keep POMALYST and all medicines out of the reach of children.

General information about the safe and effective use of POMALYST

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take POMALYST for conditions for which it was not prescribed. Do not give POMALYST to other people, even if they have the same symptoms you have. It may harm them and may cause birth defects.

If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about POMALYST that is written for health professionals.

For more information, call 1-888-423-5436 or go to www.CelgeneRiskManagement.com.

What are the ingredients in POMALYST?

Active ingredient: pomalidomide
Inactive ingredients: mannitol, pregelatinized starch, and sodium stearyl fumarate.

The 1-mg capsule shell contains gelatin, titanium dioxide, FD&C blue 2, yellow iron oxide, white ink, and black ink.
The 2-mg capsule shell contains gelatin, titanium dioxide, FD&C blue 2, yellow iron oxide, FD&C red 3, and white ink.
The 3-mg capsule shell contains gelatin, titanium dioxide, FD&C blue 2, yellow iron oxide, and white ink.
The 4-mg capsule shell contains gelatin, titanium dioxide, FD&C blue 1, FD&C blue 2, and white ink.


This Medication Guide has been approved by the U.S. Food and Drug Administration.

Manufactured for: Celgene Corporation, Summit, NJ 07901

Revised: April 2015

POMALYST®, REVLIMID®, THALOMID® and POMALYST REMS® are registered trademarks of Celgene Corporation.
Pat. http://www.celgene.com/therapies

© 2005-2015 Celgene Corporation   All rights reserved.

POMMG.004 04/2015

Pomalyst® (pomalidomide) Capsules, 1 mg - 21 Count Bottle Label

Pomalyst (pomalidomide) Capsules, 1 mg - 21 Count Bottle Label


Pomalyst® (pomalidomide) Capsules, 1 mg - 100 Count Bottle Label

Pomalyst (pomalidomide) Capsules, 1 mg - 100 Count Bottle Label


Pomalyst® (pomalidomide) Capsules, 2 mg - 21 Count Bottle Label

Pomalyst (pomalidomide) Capsules, 2 mg - 21 Count Bottle Label


Pomalyst® (pomalidomide) Capsules, 2 mg - 100 Count Bottle Label

Pomalyst (pomalidomide) Capsules, 2 mg - 100 Count Bottle Label


Pomalyst® (pomalidomide) Capsules, 3 mg - 21 Count Bottle Label

Pomalyst (pomalidomide) Capsules, 3 mg - 21 Count Bottle Label


Pomalyst® (pomalidomide) Capsules, 3 mg - 100 Count Bottle Label

Pomalyst (pomalidomide) Capsules, 3 mg - 100 Count Bottle Label


Pomalyst® (pomalidomide) Capsules, 4 mg - 21 Count Bottle Label

Pomalyst (pomalidomide) Capsules, 4 mg - 21 Count Bottle Label


Pomalyst® (pomalidomide) Capsules, 4 mg - 100 Count Bottle Label

Pomalyst (pomalidomide) Capsules, 4 mg - 100 Count Bottle Label



POMALYST 
pomalidomide capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:59572-501
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
POMALIDOMIDE (UNII: D2UX06XLB5) (POMALIDOMIDE - UNII:D2UX06XLB5) POMALIDOMIDE 1 mg
Inactive Ingredients
Ingredient Name Strength
MANNITOL (UNII: 3OWL53L36A)  
STARCH, CORN (UNII: O8232NY3SJ)  
SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)  
Product Characteristics
Color YELLOW, BLUE Score no score
Shape CAPSULE Size 14mm
Flavor Imprint Code POML;1;mg
Contains     
Packaging
# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:59572-501-21 21 in 1 BOTTLE; Type 0: Not a Combination Product
2 NDC:59572-501-00 100 in 1 BOTTLE; Type 0: Not a Combination Product
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA204026 02/18/2013
POMALYST 
pomalidomide capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:59572-502
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
POMALIDOMIDE (UNII: D2UX06XLB5) (POMALIDOMIDE - UNII:D2UX06XLB5) POMALIDOMIDE 2 mg
Inactive Ingredients
Ingredient Name Strength
MANNITOL (UNII: 3OWL53L36A)  
STARCH, CORN (UNII: O8232NY3SJ)  
SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)  
Product Characteristics
Color ORANGE, BLUE Score no score
Shape CAPSULE Size 18mm
Flavor Imprint Code POML;2;mg
Contains     
Packaging
# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:59572-502-21 21 in 1 BOTTLE; Type 0: Not a Combination Product
2 NDC:59572-502-00 100 in 1 BOTTLE; Type 0: Not a Combination Product
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA204026 02/18/2013
POMALYST 
pomalidomide capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:59572-503
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
POMALIDOMIDE (UNII: D2UX06XLB5) (POMALIDOMIDE - UNII:D2UX06XLB5) POMALIDOMIDE 3 mg
Inactive Ingredients
Ingredient Name Strength
MANNITOL (UNII: 3OWL53L36A)  
STARCH, CORN (UNII: O8232NY3SJ)  
SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)  
Product Characteristics
Color GREEN, BLUE Score no score
Shape CAPSULE Size 18mm
Flavor Imprint Code POML;3;mg
Contains     
Packaging
# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:59572-503-21 21 in 1 BOTTLE; Type 0: Not a Combination Product
2 NDC:59572-503-00 100 in 1 BOTTLE; Type 0: Not a Combination Product
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA204026 02/18/2013
POMALYST 
pomalidomide capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:59572-504
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
POMALIDOMIDE (UNII: D2UX06XLB5) (POMALIDOMIDE - UNII:D2UX06XLB5) POMALIDOMIDE 4 mg
Inactive Ingredients
Ingredient Name Strength
MANNITOL (UNII: 3OWL53L36A)  
STARCH, CORN (UNII: O8232NY3SJ)  
SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)  
Product Characteristics
Color BLUE, BLUE Score no score
Shape CAPSULE Size 18mm
Flavor Imprint Code POML;4;mg
Contains     
Packaging
# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:59572-504-21 21 in 1 BOTTLE; Type 0: Not a Combination Product
2 NDC:59572-504-00 100 in 1 BOTTLE; Type 0: Not a Combination Product
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA NDA204026 02/18/2013
Labeler - Celgene Corporation (174201137)

Revised: 4/2015
Document Id: 24e9ecda-09f0-4c56-9c6f-0c67236a5e36
Set id: 2b25ef01-5c9e-11e1-b86c-0800200c9a66
Version: 7
Effective Time: 20150430
 
Celgene Corporation